NBTXR3

Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation

Retrieved on: 
Tuesday, April 2, 2024
NBTXR3, Lung cancer, NSCLC, Patient, Observation, Cancer, Nanobiotix, NANO, Radiation, MD, University, MD Anderson Cancer Center, Safety, Pharmaceutical industry

The Phase 1 study (“Study 2020-0123”) is being conducted by The University of Texas MD Anderson Cancer Center (“MD Anderson”) as part of an ongoing strategic collaboration with Nanobiotix.

Key Points: 
  • The Phase 1 study (“Study 2020-0123”) is being conducted by The University of Texas MD Anderson Cancer Center (“MD Anderson”) as part of an ongoing strategic collaboration with Nanobiotix.
  • “NBTXR3 is designed as a product candidate with the potential to improve treatment outcomes for patients with cancer in any setting where radiotherapy is a part of the treatment regimen.
  • “We believe the injection feasibility and favorable safety profile we have observed from the completed dose escalation part of this Phase 1 lung cancer study could pave the way for additional clinical development of NBTXR3 for patients with inoperable, recurrent lung cancer and patients amenable to re-irradiation.”
    The completed dose escalation part of Study 2020-0123 established the recommended Phase 2 dose after determination of injection feasibility and observation of a favorable safety profile.
  • The expansion part of the study, further evaluating safety and early signals of efficacy, is ongoing.

LianBio Announces Completion of Strategic Review

Retrieved on: 
Tuesday, February 13, 2024
ADS, NBTXR3, OTC, Sale, Citibank, Wind, American depositary receipt, Sarbanes, Patient, Tax, Workforce, Book

“In October 2023, the Board of Directors initiated a comprehensive strategic review of the Company, including numerous options for the future of the Company, as our commitment to represent the best interests of LianBio and shareholders,” said Konstantin Poukalov, Founder and Executive Chairman of LianBio’s Board.

Key Points: 
  • “In October 2023, the Board of Directors initiated a comprehensive strategic review of the Company, including numerous options for the future of the Company, as our commitment to represent the best interests of LianBio and shareholders,” said Konstantin Poukalov, Founder and Executive Chairman of LianBio’s Board.
  • However, there is no guarantee that any shareholder’s original investment, or any material amount, will be recovered.
  • The Company expects to pay the dividend to its holders of record of ordinary shares on or about March 11, 2024.
  • The Depositary will re-open the books for ADS cancellations at the close of business in New York City on March 18, 2024.

Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study

Retrieved on: 
Monday, January 29, 2024
Head, NBTXR3, Patient, Johnson & Johnson, NANO, Cancer, Pharmaceutical industry

PARIS and CAMBRIDGE, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced achievement of operational requirements in NANORAY-312, an ongoing pivotal Phase 3 study evaluating potential first-in-class radioenhancer NBTXR3 for elderly patients with head and neck cancer, resulting in a $20M milestone payment from strategic partner Janssen Pharmaceutica NV (“Janssen”), a Johnson & Johnson company.

Key Points: 
  • PARIS and CAMBRIDGE, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced achievement of operational requirements in NANORAY-312, an ongoing pivotal Phase 3 study evaluating potential first-in-class radioenhancer NBTXR3 for elderly patients with head and neck cancer, resulting in a $20M milestone payment from strategic partner Janssen Pharmaceutica NV (“Janssen”), a Johnson & Johnson company.
  • “This first milestone payment related to our ongoing pivotal Phase 3 study evaluating NBTXR3 for patients with head and neck cancer represents another step forward in our pathway to bring NBTXR3 to registration,” said Laurent Levy, Nanobiotix co-founder and chairman of the executive board.
  • “We look forward to continued collaboration with Janssen as we work to deliver the potential benefits of NBTXR3 to millions of patients around the world.”
    This $20M represents the first applicable development milestone from the global licensing agreement executed between Nanobiotix and Janssen (For more details, please consult the press release dated 4 December 2023).

Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets

Retrieved on: 
Tuesday, December 26, 2023
NBTXR3, Johnson & Johnson, Janssen, Cancer, Head, Patient, NANO, Pharmaceutical industry

“Our collaboration strategy for the development and commercialization of NBTXR3 is rooted in a shared commitment to delivering the potential first-in-class radioenhancer to millions of patients around the world,” said Laurent Levy, Nanobiotix co-founder and chairman of the executive board.

Key Points: 
  • “Our collaboration strategy for the development and commercialization of NBTXR3 is rooted in a shared commitment to delivering the potential first-in-class radioenhancer to millions of patients around the world,” said Laurent Levy, Nanobiotix co-founder and chairman of the executive board.
  • “LianBio has served as an important partner in expanding our clinical development program in Asia, particularly with their support for our ongoing pivotal phase 3 study evaluating NBTXR3 in head and neck cancer.
  • We look forward to continued momentum in our program and moving NBTXR3 toward global registration.”
    This agreement consolidates global development and commercialization rights of NBTXR3 with Janssen; streamlines the global alliance for co-development and registration of the radioenhancer with Nanobiotix; and includes all previously agreed upon economic terms between Nanobiotix and LianBio, including the Nanobiotix entitlement to receive up to an aggregate $220 million in potential contingent, development and commercialization milestone payments (less $15 million already paid to Nanobiotix by LianBio) along with tiered, low double-digit royalties based on net sales of NBTXR3 in Asian territories.
  • Following the deal close, LianBio will support the transition of the asset to Janssen for a period no longer than six months.

LianBio Enters into Agreement Assigning its Rights for NBTXR3 in China and Other Asian Markets

Retrieved on: 
Tuesday, December 26, 2023
NBTXR3, Johnson & Johnson, Nanobiotix, Janssen, Head, Patient, Neck, Pharmaceutical industry

Under the terms of the agreement, LianBio will receive a one-time payment of $25 million.

Key Points: 
  • Under the terms of the agreement, LianBio will receive a one-time payment of $25 million.
  • In addition, LianBio is eligible to receive a sales milestone payment of $5 million.
  • Following the deal close, LianBio will support the transition of the asset to Janssen for a period no longer than six months.
  • In July 2023, Nanobiotix granted Janssen a worldwide exclusive license, excepting territories previously licensed to LianBio, for the co-development and commercialization of NBTXR3.

NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update

Retrieved on: 
Monday, November 13, 2023
Webcast, Lung, Pancreatic cancer, Johnson & Johnson, University, Conference call, Clinical trial, ESMO, Phase 1, NANO, PFS, Patient, Dilute budgerigar mutation, CET, Monroe Dunaway Anderson, BofA Securities, DCR, Nanobiotix, NBTXR3, Conference, EIB, Bloomberg, RT, Cancer, European Investment Bank, Survival, Janssen, Oncology, MD Anderson Cancer Center, OS, AACR, Pharmaceutical industry, Security (finance), Sales, Medical imaging, Palladium, Bank, Euronext

PARIS and CAMBRIDGE, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today provided an update on operational progress and reported financial results for the third quarter of 2023.

Key Points: 
  • “Our robust NBTXR3 clinical program continues to demonstrate potentially transformative efficacy and well-tolerated safety across indications and patient types, including elderly and vulnerable populations.
  • Nanobiotix will host a conference call and live audio webcast on Tuesday, November 14, 2023, at 8:00 am ET / 2:00 pm CET, prior to the open of the U.S. market.
  • During the call, Laurent Levy, chief executive officer, and Bart van Rhijn, chief financial officer, will briefly review the Company’s operational progress, provide an update on business activities for the third quarter of 2023, and review the latest data presented at the 2023 Annual Congress of the European Society for Medical Oncology (ESMO), before taking questions from participants.
  • A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the Company’s website.

NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M

Retrieved on: 
Thursday, November 2, 2023
Common stock, Cyprus Securities and Exchange Commission, Exercise, SVB Securities, American depositary receipt, Code, Partnership, EIB, State Street, Guggenheim, Janssen, Tax, Guggenheim Partners, Qatar Investment Authority, Jefferies Group, Telephone, Form, Baillie Gifford, Cancer, Patient, Security (finance), The 8th Floor, Research, Floor, NANO, ADS, Madison Avenue, NBTXR3, ISIN, Private, Attention, Prospectus, Commercial code, Pharmaceutical industry, EU, Euronext

The closing of the Global Offering is not conditioned on the closing of the Concurrent Private Placement.

Key Points: 
  • The closing of the Global Offering is not conditioned on the closing of the Concurrent Private Placement.
  • Jefferies LLC, Leerink Partners and Guggenheim are acting as global coordinators and joint bookrunners for the Global Offering.
  • The Global Offering is subject to an underwriting agreement, which was entered into on November 2, 2023.
  • The expected use of proceeds represents the Company’s intentions based upon its current plans and business conditions.

NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M

Retrieved on: 
Thursday, November 2, 2023
Common stock, Cyprus Securities and Exchange Commission, Exercise, SVB Securities, American depositary receipt, Code, Partnership, EIB, State Street, Guggenheim, Janssen, Tax, Guggenheim Partners, Qatar Investment Authority, Jefferies Group, Telephone, Form, Baillie Gifford, Cancer, Patient, Security (finance), The 8th Floor, Research, Floor, NANO, ADS, Madison Avenue, Note, AMF, NBTXR3, ISIN, Private, Attention, Risk, Prospectus, Commercial code, Cryptocurrency, Pharmaceutical industry, EU, Euronext

The closing of the Global Offering is not conditioned on the closing of the Concurrent Private Placement.

Key Points: 
  • The closing of the Global Offering is not conditioned on the closing of the Concurrent Private Placement.
  • Jefferies LLC, Leerink Partners and Guggenheim are acting as global coordinators and joint bookrunners for the Global Offering.
  • The Global Offering is subject to an underwriting agreement, which was entered into on November 2, 2023.
  • The expected use of proceeds represents the Company’s intentions based upon its current plans and business conditions.

NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant

Retrieved on: 
Wednesday, November 1, 2023
Common stock, Cyprus Securities and Exchange Commission, Exercise, SVB Securities, American depositary receipt, PIK, Code, Partnership, Nanobiotix, EIB, State Street, Tax, Guggenheim Partners, EDGAR, Jefferies Group, Telephone, Form, 3rd Floor, Cancer, Patient, Security (finance), Park Avenue, The 8th Floor, Research, Floor, Application, NANO, ADS, Madison Avenue, Note, AMF, European Investment Bank, Documentation, Milestone, NBTXR3, ISIN, Private, Attention, BofA Securities, Risk, Prospectus, Commercial code, Pharmaceutical industry, Bank, EU, Euronext

The U.S. Offering and the European Offering are referred to, together, as the “Global Offering”.

Key Points: 
  • The U.S. Offering and the European Offering are referred to, together, as the “Global Offering”.
  • The closing of the Global Offering is not conditioned on the closing of the Concurrent Private Placement.
  • Leerink Partners, Guggenheim Securities and H.C. Wainwright & Co. are also acting as joint bookrunners for the Global Offering.
  • All securities to be sold in the Global Offering and the Concurrent Private Placement will be offered by the Company.

NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant

Retrieved on: 
Wednesday, November 1, 2023
Common stock, Cyprus Securities and Exchange Commission, Exercise, SVB Securities, American depositary receipt, PIK, Code, Partnership, Nanobiotix, EIB, State Street, Tax, Guggenheim Partners, EDGAR, Jefferies Group, Telephone, Form, 3rd Floor, Cancer, Patient, Security (finance), Park Avenue, The 8th Floor, Research, Floor, NANO, ADS, Madison Avenue, European Investment Bank, Documentation, Milestone, NBTXR3, ISIN, Private, Attention, BofA Securities, Prospectus, Commercial code, Pharmaceutical industry, Bank, EU, Euronext

The U.S. Offering and the European Offering are referred to, together, as the “Global Offering”.

Key Points: 
  • The U.S. Offering and the European Offering are referred to, together, as the “Global Offering”.
  • The closing of the Global Offering is not conditioned on the closing of the Concurrent Private Placement.
  • Leerink Partners, Guggenheim Securities and H.C. Wainwright & Co. are also acting as joint bookrunners for the Global Offering.
  • All securities to be sold in the Global Offering and the Concurrent Private Placement will be offered by the Company.